Table 4.

Immunotherapy Combined with Targeted Therapy for HCC

Drugs	Phase	Participants	ClinicalTrials.gov	Start Date	Status	Reference
Camrelizumab + Apatinib	II	20	NCT04297202	December 1, 2019	Recruiting	[143]
Cabozantinib + Atezolizumab	III	740	NCT03755791	June 10, 2018	Active, not recruiting	[144]
Regorafenib + Pembrolizumab	I	58	NCT03347292	June 18, 2018	Completed
Regorafenib + Avelumab	I/II	482	NCT03475953	May 4, 2018	Recruiting	[145]
Cabozantinib + Nivolumab	I	15	NCT03299946	May 14, 2018	Completed	[146]
Cabozantinib + Durvalumab	I/II	117	NCT03539822	October 22, 2018	Active, not recruiting
Ramucirumab + Durvalumab	I	85	NCT02572687	February 19, 2016	Completed
Bevacizumab + Erlotinib	II	45	NCT01180959	April 14, 2011	Completed	[147]
Sorafenib + Nivolumab	II	24	NCT03439891	April 16, 2018	Active, not recruiting
Tivozanib + Durvalumab	I/II	42	NCT03970616	September 30, 2019	Terminated	[148]
Tislelizumab + Lenvatinib	II	30	NCT04834986	April 30, 2021	Not yet recruiting
Camrelizumab + Apatinib	II	40	NCT04826406	February 3, 2021	Recruiting
Atezolizumab + Bevacizumab	III	668	NCT04102098	December 31, 2019	Active, not recruiting	[149]
Durvalumab + Tremelimumab	III	1324	NCT03298451	October 11,2017	Active, not recruiting	[150]
Donafenib + Sintilimab	II	30	NCT05162352	December 4, 2021	Recruiting
Camrelizumab + Apatinib	III	674	NCT04639180	April 1, 2021	Not recruiting